MindMed Calls FDA Experts To Validate LSD Drug Development Strategy
In a new chapter of the management quarrel between MindMed (NASDAQ: MNMD) executives and shareholder group FCM Holdings, t
MindMed’s Q3 2022 Financials & Business, Setting The Stage For Phase 3 Trials
Clinical-stage biotech company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported its financial results and updated on its programs pipeline of the third quarter ended September 30, 2022.
MindMed’s First Patient Dosing Clinical Trial With LSD For Treatment Of Generalized Anxiety Disorder
The clinical-stage biopharma company Mind Medicine -also known as MindMed (NASDAQ: MNMD), which recently made headlines reg
MindMed: Financial And Business Results For Q2 2022, Management And Pipeline Changes
MindMed (NASDAQ: MNMD), which recently received a letter on behalf of one of its shareholders calling for a new business strategy and offer